{
  "pmcid": "12137697",
  "sha256": "4c79e859b1af3d8aed4700f731d74b781350dca33ba25265f76c6a1b5bedada2",
  "timestamp_utc": "2025-11-09T22:16:20.131194+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.86315789473684,
    "reading_ease": 32.57043859649124,
    "word_count": 228
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors with Pleural Spread or Recurrence"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Participants": {
        "score": 2,
        "evidence": "Forty-five adult patients with TETs and pleural dissemination were enrolled between August 1, 2021, and February 29, 2024."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved S-HITOC with 25 mg/m² doxorubicin and 50 mg/m² cisplatin."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety and efficacy of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy (S-HITOC) in this context."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of treatment-related adverse events of grade ≥3, measured perioperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Blinding": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Forty-five adult patients with TETs and pleural dissemination were enrolled between August 1, 2021, and February 29, 2024."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Eight patients (17.8%) experienced grade ≥3 adverse events."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The 2-year progression-free survival (PFS) and overall survival (OS) rates were 82.8% and 100.0%, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "Eight patients (17.8%) experienced grade ≥3 adverse events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05446935."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}